openPR Logo
Press release

HDAC Inhibitors Market - Increasing R&D activities for cancer is expected to boost HDAC inhibitors market during the forecast period

10-20-2021 09:32 AM CET | Health & Medicine

Press release from: Coherent Market Insights

HDAC Inhibitors Market

HDAC Inhibitors Market

Overview

HDAC inhibitors are a kind of anti-cancer drug that works by causing cell cycle arrest, apoptosis, and death in cancer cells through non-epigenetic or epigenetic control. HDAC inhibitors (HDACi) are potential medicines that have already demonstrated promise in oncological applications such as cancer detection, treatment, and prognostic. Vorinostat (Merck & Co. Inc.) is a new medication that is used to treat epidermal T cell lymphoma as it progresses, relapses, or while being treated. Current candidates have shown promise in pre-clinical and clinical studies for a variety of illnesses, including neurological disorders, heart problems, and HIV infections.

Request for a Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/1294

Drivers

The demand for HDAC inhibitors is expected to increase in the near future due to an increasing number of applications in different therapeutic areas such as neurodegenerative diseases such as Huntington's and Alzheimer's disease, Polycythemia vera, inflammation, and essential Thrombocythemia, Myelofibrosis.

Growing cancer-related R&D is projected to drive the global HDAC inhibitors market in the coming years. Novartis obtained FDA clearance in February 2015 for Farydak capsules in combination with dexamethasone and bortezomib* for patients with multiple myeloma who had previously undergone at least two regimens. The FDA's authorization of a few HDAC inhibitors for cancer therapy has sparked interest in developing novel anti-cancer medicines. Furthermore, one of the primary drivers of the global HDAC inhibitors market is increased R&D efforts for the treatment of cancer and other neurological illnesses. Around 350 clinical studies utilizing HDACi as a solo therapy or in combination with other targeted medicines against various human illnesses have been completed or are in the works.

Restraints

Doubts concerning HDAC inhibitors' therapeutic potential and strict reimbursement rules are anticipated to stifle the global HDAC inhibitors market growth in the foreseeable future. Obtaining compensation and coverage for newly authorized medications by the FDA or other international regulatory agencies might take a long time.

Request Here PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1294

Regional Analysis

Due to the increased prevalence of cancer and demand for cancer treatments in the area, North America is projected to retain a prominent position in the global HDAC inhibitors market. According to the American Cancer Society, the United States will see 1,688,780 new cancer cases and 600,920 cancer-related deaths in 2017. Better financing for cancer research and development, as well as an increasing need for effective treatments with reduced costs. Congress passed the 21st Century Cures Act in 2017, authorizing $1.8 billion in funding for the Cancer Moonshot program over a seven-year period. Due to the rising presence of well-established healthcare infrastructure, early acceptance of novel medicines, and growing R&D expenditure capacity, Europe is anticipated to see remarkable growth over the forecast period (2017–2025).

Competitive Landscape

Key companies contributing in the global HDAC inhibitors market are Chipscreen, GSK, Novartis, Celldex, AbbVie, Spectrum Pharmaceuticals, Celgene, Syndax, Onxeo, Merck, and Chroma Therapeutics.

Various pharmaceutical firms are increasingly investing in R&D and preclinical activities of HDACi for different applications. In January 2018, Syndax and Genentech extended their study of the effects of combining PD-L1 and HDAC inhibitors. This new contract permits Genentech to test its Tecentriq with Syndax’s entinostat in a subset of breast cancer patients.

Purchase this Report Here – https://www.coherentmarketinsights.com/insight/buy-now/1294

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HDAC Inhibitors Market - Increasing R&D activities for cancer is expected to boost HDAC inhibitors market during the forecast period here

News-ID: 2434193 • Views: 230

More Releases from Coherent Market Insights

Background Music Market Current Trend, Technology is Expected to Increase at a C …
Global background music market generated revenue of US$ 1.35 billion in 2017. By 2026, the background music market is expected to be valued at US$ 2.31 billion with a CAGR of 6.3% over the forecast period. Music in various styles and permutations such as amplified or acoustic, instrumental or vocal, or any other format is a universal and ubiquitous cultural expression. It represents human culture, thus can have immense
COVID-19 Nasal Swab Test Market with Size, Share, Growth Insight, Trend, future …
Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Global COVID-19 Nasal Swab Test Market Report that covers exclusive and analytical data through the span of seven years between 2021-2027. This report is exclusive and encompasses in-depth analysis and industry insights on
Latin America Smart Insulin Pen Market is expected to reach US$ 10.42 Million by …
Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Latin America Smart Insulin Pen Market Report that covers exclusive and analytical data through the span of seven years between 2021-2027. This report is exclusive and encompasses in-depth analysis and industry insights on
Predictive Maintenance Market Will Generate Massive Revenue US$ 17,700.8 Mn By 2 …
The global Predictive Maintenance market is estimated to account for US$ 17.7 Billion By 2026 The Predictive Maintenance Market research provides analytical information on market dynamics, including both qualitative and quantitative aspects of the industry within each of the study's regions and nations. The study is curated utilizing significant primary and secondary research, and it has been thoroughly reviewed by industry experts and professionals. A basic predictive maintenance solution has a

All 5 Releases


More Releases for HDAC

HDAC Inhibitors Market Report 2020: Annual Estimates & Forecasts 2027
The “HDAC Inhibitors Market” Research Report 2020-2027 is a specialized and in-depth study of the HDAC Inhibitors industry with a focus on the global market trend. The report aims to provide an overview of global HDAC Inhibitors Market with detailed market segmentation by component, deployment model, end-user and geography. The global HDAC Inhibitors Market is expected to witness high growth during the forecast period. The report provides key statistics on
HDAC Inhibitors Market - Future and Technological Advancement 2026
HDAC inhibitors refers to the class of anti-cancer agents that play a vital role in non-epigenetic or epigenetic regulation, inducing cell cycle arrest, apoptosis, and death of cancer cells. Histone deacetylase inhibitors (HDACi) are promising therapeutics, which have already shown potential for oncological applications such as cancer detection, diagnosis, and prognosis. For instance, Vorinostat (Merck & Co. Inc.) is a novel drug used in the management of cutaneous T cell
HDAC Inhibitors Market - Trends and Opportunities 2017 - 2025
Regional segmentation of HDAC inhibitors market by Coherent Market Insights, includes North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is expected to hold a dominant position in the market due to growing incidence of cancer and rising demand for cancer therapeutics in the region. According to American Cancer Society, in 2017, 1,688,780 new cancer cases and 600,920 deaths due to cancer are estimated to occur
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,
Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
The “Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017″ report provides a comprehensive analysis of HDAC drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential HDAC inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding,